Grandem MD Tablet contains Granisetron 1mg, a selective 5-HT3 receptor antagonist used primarily for the prevention and treatment of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative conditions. Granisetron acts by blocking serotonin receptors located on vagal nerve terminals and in the chemoreceptor trigger zone, thereby inhibiting the emetic signals transmitted to the brain. This medication is particularly effective in managing acute emesis caused by highly and moderately emetogenic cancer treatments. Grandem MD Tablet is typically administered orally, with dosage and duration tailored according to the specific clinical scenario and patient response. The drug is well absorbed with a rapid onset of action and a favorable safety profile. Common adverse effects may include headache, constipation, and transient elevation of liver enzymes, though these are generally mild and self-limiting. Caution is advised in patients with hepatic impairment, and it should be used under medical supervision to avoid potential drug interactions. Overall, Grandem MD Tablet offers a reliable and targeted approach to improving patient comfort and compliance during emetogenic therapies by effectively controlling nausea and vomiting.